ABX-002
Phase 2Small molecule
ABX-002 is one of 100 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
115 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Lunesta
Akero TherapeuticsApproved
Fanapt
VVanda Pharmaceuticals
Approved
Ultram
WWim Janssens
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Ssris
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Major Depressive Disorder1 trial
Bipolar Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABX-002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAutobahn Therapeutics, Inc.